Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care
Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Attending Physician, Memorial Sloan-Kettering Cancer Center, states that any organizational change that shifts payment and risk to providers will improve quality. Dr. Bach says that quality can be improved if providers seek to manage costs in a way that promotes high-quality care while making decisions based on evidence and pathways.
This video was taken on November 16 at AJMC's Translating Evidence-Based Research Into Value-Based Decisions in Oncology.
The study in Health Affairs published by Samir Soneji, PhD, an assistant professor at Dartmouth's Geisel School of Medicine and The Dartmouth Institute for Health Policy & Clinical Practice, found that despite a sharp rise in healthcare spending,caner mortality rates are very high in the US compared to Western Europe.
The Patient Access Network or PAN Foundation formed more than 10 years ago, partially in response to the Medicare Part D benefit. It helps patients meet cost-sharing requirements across dozens of diseases, including 25 in oncology; Evidence-Based Oncology, a publication of The American Journal of Managed Care, invited PAN Foundation President and CEO Dan Klein to discuss its role in immuno-oncology.
Suzanne F. Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform, will be the keynote speaker at the spring meeting of the ACO and Emerging Healthcare Delivery Coalition, to be held April 30 and May 1, 2015, in San Diego, California. The ACO Coalition, an initiative of The American Journal of Managed Care, brings together stakeholders from across the healthcare spectrum interested in sharing best practices relative to the changing delivery and payment models.
The use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time, a new study published in the American Journal of Clinical Oncology, has found, and patients treated with the therapy have better survival than those treated with surgery alone, researchers say.
The study found that following Genetech's decision to restrict the distribution of it's 3 popular cancer medications through specific specialty distributors, patient access to the drugs has reduced while costs have increased.